Published in Oncology Business Week, December 3rd, 2006
The study is designed to determine the maximum tolerated dose and to evaluate the safety and efficacy of BZL101. Recruitment and testing will take place at 10 clinical sites in the U.S. The company expects to begin patient enrollment early in the first quarter of 2007. Debu Tripathy, director of the Komen/UT Southwestern Breast Cancer Research Program at the University of Texas Southwestern Medical Center in Dallas, will serve as the overall Principal...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week